PTO/S8/05a (01-10)
Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1.99)

	Application Number		10598086
	Filing Date		2006-08-17
	First Named Inventor Hirosl		hi Kawazoe et al.
	Art Unit		1773
	Examiner Name	Jan N	I. Ludiow
	Attorney Docket Numb	er	062904

	U.S.PATENTS								Remove
Examiner Initial*	Cite No				Rele	es,Columns,Lines where vant Passages or Relevant res Appear			
	1								
If you wis	h to ac	id additional U.S. Pat	nt citatio	n inform	ation p	lease click the	Add button.		Add
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove
Examiner Initial*	Cite No Publication Number					Name of Pate of cited Docu	r Patentee of Applicant Polovant Das		es,Columns,Lines where want Passages or Relevant res Appear
	1								
If you wis	h to ac	ld additional U.S. Pub	lished Ap	plication	n citatio	n information p	lease click the Ad	d butto	on. Add
				FORE	GN PA	TENT DOCUM	ENTS		Remove
Evaminar	Cito	Foreign Dogument	Countr		Kind	Bublication	Name of Patente	e or	Pages,Columns,Lines

Examiner Initial*		Foreign Document Number ³	Kind Code ⁴	Publication	Name of Patentee or Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	T6	
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10598086
iling Date		2006-08-17
irst Named Inventor	Hirosl	ni Kawazoe et al.
Art Unit		1773
xaminer Name Jan M		. Ludlow
Attorney Docket Number		062904

	1	U.S.	Final Office Action dated August 18, 2011, issued in U.S. Patent Ap	oplication No. 13/026,	875 (071668C)	
	2	U.S.	Final Office Action dated July 15, 2011, issued in U.S. Patent Appli	cation No. 12/501,10!	3 (042717E)	
	3	U.S.	Non-Final Office Action dated July 19, 2011 issued in U.S. Patent A	Application 12/501,12	D (042717F)	
	4	U.S.	Non-Final Office Action dated July 12, 2011 issued in U.S. Patent A	Application 12/914,01	D (042717A2)	
	5	U.S.	Non-Final Office Action dated July 8, 2011, issued in U.S. Patent A	pplication No. 12/501	,078 (042717C)	
If you wis	sh to a	dd add	ditional non-patent literature document citation information pl	ease click the Add	button Add	
			EXAMINER SIGNATURE			
Evamina	r Sian	atura		Data Considered		

16e Kind Code of USPTO Potent Documents at even USPTO_COLV or MPEP 90.04. 2 fitter of tice that issued the document, by the Involved (WIPO) Standard \$7.3.) 2 for Uspicesee plated for colument, be endouding on the purpose or part precedes the sent under the plated document. If Involved the Colument on the USPTO Standard \$7.3.) 2 for USPTO Standard \$7.3. 2 for USPTO Standard \$7.4. 2 for USPTO Stand

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10598086
Filing Date		2006-08-17
First Named Inventor	Hirosh	n Kawazoe et al.
Art Unit		1773
Examiner Name Jan M		. Ludiow
Attorney Docket Number		062904

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a deeping paterl office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to item individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lee C. Wright/	Date (YYYY-MM-DD)	2011-09-08
Name/Brint	Loo C Widaht	Registration Number	41441

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1445, Alexandria, V.3.2311-4450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public fifthe record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.